When disease discriminates: Women and COPD

December 14, 2007

Women have made a good deal of welcome progress in the last several decades, but at least one advance is unwanted: chronic obstructive pulmonary disease (COPD) is on the rise in women in prevalence, morbidity and mortality. By 2000, the number of women dying from COPD surpassed the number of men. But the rising number of cases in women has not been matched by medical understanding of the disease's apparent gender-bias.

"The disease expression of COPD in women is different than in men," says Fernando Martinez, M.D., professor of internal medicine at the University of Michigan and senior author on the review, which appears in the second issue for December of the American Journal of Respiratory and Critical Care Medicine, published by the American Thoracic Society. "The main reason that we did this study was to highlight that there really are gender differences in the disease, and that they require additional study."

Dr. Martinez and his colleagues assessed the state of medical and scientific knowledge on gender and COPD and found some consistent patterns. Not only are the manifestations of the disease different in men and women, but the risk factors, symptoms, disease, progression, and even diagnosis, are markedly different between the sexes.

COPD actually comprises what used to be considered two distinct diseases: emphysema, or an abnormality in the lung tissue, and chronic bronchitis, an obstruction of the airways. One of the major gender differences in the manifestation of COPD is that women tend to develop more airway obstruction, whereas men tend to develop a more emphysematic manifestation of the disease. But why that is so is still unclear.

"It may reflect differences in exposures, or [genetic] differences in how males and females manifest damage," said Dr. Martinez. "Or it may have nothing to do with underlying genetic differences that are gender-based."

Women also seem to more prone than men to developing COPD from their exposures to risk factors, such as cigarette smoke and smoke from biomass fuels used for cooking in many developing regions of the world. Ironically, a number of studies have also shown that female smokers have a harder time quitting and remaining tobacco-free than males. Because COPD can develop over decades, a significant portion of current cases can be traced back to a rising smoking epidemic among women that began in the 1950s.

Women may be more susceptible to developing COPD from their exposures, but they also predominate among COPD patients who have never smoked, and may have gender-linked genetic factors that predispose them to developing the disease.

And once sick, women also have different experiences than men. They are less likely to be correctly diagnosed or offered appropriate diagnostic tests for COPD. They report more severe shortness of breath, more anxiety and depression. And according to some studies, they report having a lower quality of life because of their disease.

The fact that COPD differs between men and women is undisputed. But answering questions as to how and why, Dr. Martinez emphasizes, is critical in advancing the medical and scientific understanding of the disease. How do men and women differ in exposures and other risk factors? Are the differences biological or behavioral? How do exposure patterns affect their susceptibility to developing the disease and its manifestation? Why does COPD progress more swiftly in women? Do outcomes differ because of gender bias in diagnosis, physiological differences, or phenotypic differences in their disease?

"Whatever the question, whether it is about the biological nature of the disease or clinical impact of therapeutic studies, you have to have a gender analysis," says Dr. Martinez. "It's an absolutely crucial parameter. Appropriate gender analysis has to be taken into account because it may be instrumental in allowing you to interpret what you're trying to study."
-end-


American Thoracic Society

Related Mortality Articles from Brightsurf:

Being in treatment with statins reduces COVID-19 mortality by 22% to 25%
A research by the Universitat Rovira i Virgili (URV) and Pere Virgili Institut (IISPV) led by LluĂ­s Masana has found that people who are being treated with statins have a 22% to 25% lower risk of dying from COVID-19.

Mortality rate higher for US rural residents
A recent study by Syracuse University sociology professor Shannon Monnat shows that mortality rates are higher for U.S. working-age residents who live in rural areas instead of metro areas, and the gap is getting wider.

COVID-19, excess all-cause mortality in US, 18 comparison countries
COVID-19 deaths and excess all-cause mortality in the U.S. are compared with 18 countries with diverse COVID-19 responses in this study.

New analysis shows hydroxychloroquine does not lower mortality in COVID-19 patients, and is associated with increased mortality when combined with the antibiotic azithromycin
A new meta-analysis of published studies into the drug hydroxychloroquine shows that it does not lower mortality in COVID-19 patients, and using it combined with the antibiotic azithromycin is associated with a 27% increased mortality.

Hydroxychloroquine reduces in-hospital COVID-19 mortality
An Italian observational study contributes to the ongoing debate regarding the use of hydroxychloroquine in the current pandemic.

What's the best way to estimate and track COVID-19 mortality?
When used correctly, the symptomatic case fatality ratio (sCFR) and the infection fatality ratio (IFR) are better measures by which to monitor COVID-19 epidemics than the commonly reported case fatality ratio (CFR), according to a new study published this week in PLOS Medicine by Anthony Hauser of the University of Bern, Switzerland, and colleagues.

COVID-19: Bacteriophage could decrease mortality
Bacteriophage can reduce bacterial growth in the lungs, limiting fluid build-up.

COPD and smoking associated with higher COVID-19 mortality
Current smokers and people with chronic obstructive pulmonary disease (COPD) have an increased risk of severe complications and higher mortality with COVID-19 infection, according to a new study published May 11, 2020 in the open-access journal PLOS ONE by Jaber Alqahtani of University College London, UK, and colleagues.

Highest mortality risks for poor and unemployed
Large dataset shows that income, work status and education have a clear influence on mortality in Germany.

Addressing causes of mortality in Zambia
Despite the fact that people in sub-Saharan Africa are now living longer than they did two decades ago, their average life expectancy remains below that of the rest of the world population.

Read More: Mortality News and Mortality Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.